This company develops deep-learning AI for the early detection of diseases, starting with diabetic retinopathy. Their Nsight360 product uses camera-agnostic technology to generate rapid, accurate diagnostic reports from retinal scans. This solution aims to improve health equity by enabling efficient, affordable point-of-care evaluations, even in underserved areas.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of diabetic retinopathy cases progress undiagnosed due to limited access to specialists and the need for frequent eye exams. This is especially true in underserved communities, leading to delayed treatment and potential vision loss.
Solution
Ophthalytics offers Nsight360, an AI-powered diagnostic platform that automates the detection of diabetic retinopathy using deep-learning algorithms. Nsight360 analyzes retinal scans from various camera types, including handheld and portable devices, to generate comprehensive reports within minutes. The platform's camera-agnostic design enables point-of-care evaluations in diverse settings, even in rural patient homes. By providing rapid and accurate assessments based on existing clinical practice guidelines, Nsight360 addresses the care gap in diabetic retinopathy diagnosis, particularly for underserved populations. The AI-powered precision ensures fast and accurate results, facilitating timely interventions and improved patient outcomes.
Target Audience
The primary target audience includes healthcare providers, ophthalmologists, and organizations focused on diabetic care, particularly those serving underserved communities.
Features
- AI-powered analysis of retinal scans for diabetic retinopathy detection
- Compatible with various camera types, including stationary and portable fundus cameras
- Deep-learning algorithms based on existing clinical practice guidelines
- Rapid report generation in minutes
- Point-of-care evaluations possible in diverse settings